Skip to content
mapperlab
← Dashboard
Stock

TNDM

TANDEM DIABETES CARE INC
Health CareHealth Care EquipmentLatest close $147 of 27 marquee funds currently hold2 CUSIPs mapped
Current holders
7
27 funds tracked
Ever held
9
Current + past
New this quarter
2
Exited this quarter
0

Marquee-fund ownership over time

Aug 13, 2021Aug 9, 2024Aug 14, 2025May 15, 2026
Now
8

This quarter's activity

New positions opened

Positions exited

None.

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Renaissance Technologies re-entered$38$14-64%
Citadel Advisors$42$14-68%
Two Sigma Investments$42$14-68%
AQR Capital Management$42$14-68%
Millennium Management$42$14-68%
Point72 Asset Management re-entered$29$14-53%
D.E. Shaw$11$14+27%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Bridgewater Associates→ $23-79%
Maverick Capital 2× in & out→ $29-10%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at TANDEM DIABETES CARE INC. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
25
Filings · last 90d
28
Total on file
648
Recent SEC buffer
Most recent
Jun 4, 2026

30d / 90d windows measured from Jun 4, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 648 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · TANDEM DIABETES CARE INC

Annual figures sourced directly from TANDEM DIABETES CARE INC's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$1.01B
FY2025+8% YoY
Net income
-$204.71M
FY2025-113% YoY
EPS (diluted)
$-3.04
FY2025-107% YoY
Free cash flow(?)
-$29.67M
FY2025-500%+ YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for TANDEM DIABETES CARE INC — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Point72 Asset ManagementQ2 2026open$13$14+6%
Renaissance TechnologiesQ2 2026open$14$14-4%
Point72 Asset ManagementQ1 2026open$0.00—+0%
D.E. ShawQ3 2025open$11$14+27%
Point72 Asset ManagementQ4 2024Q2 2025$29$23-21%
Citadel AdvisorsQ3 2024open$42$14-68%
Two Sigma InvestmentsQ3 2024open$42$14-68%
AQR Capital ManagementQ3 2024open$42$14-68%
Millennium ManagementQ3 2024open$42$14-68%
Renaissance TechnologiesQ3 2024Q1 2026$38$19-50%
Maverick CapitalQ2 2023Q3 2023$32$29-10%
Maverick CapitalQ4 2021Q2 2022$137$72-48%
Bridgewater AssociatesQ3 2021Q2 2025$107$23-79%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.